AHCO: Ascending Triangle detected on 25 Mar 2026

AHCO is forming an ascending triangle pattern following the acquisition of a leading HME provider in Hawaii that expanded the company's geographic footprint to 48 states. The pattern displays solid structure (13.75/15) and clean volume confirmation (12.0/12) with a breakout score of 13.0/13. The stock sits at $11.48, pinned between key support at $10.01 and resistance at $11.12, positioned 61.6% above its 52-week low. Current volume of 2.81M shares represents 1.57x the 20-day average, indicating institutional accumulation. The overall score of 77.75/98 reflects a good-quality setup with a 63.11% win probability.

In late February 2026, AdaptHealth reported full-year 2025 results showing net loss of $70.79 million driven by a $127.99 million goodwill impairment, and provided new 2026 revenue guidance of $3.44-$3.51 billion. Fourth quarter 2025 EPS came in at -$0.76, missing consensus of $0.36, though revenue of $846.3 million beat forecasts by 1.66%. Following earnings on February 24, shares declined approximately 14%, but major shareholder Richard Cashin purchased 447,100 shares on March 20 at an average cost of $9.91 per share, a $4.4 million commitment. RBC Capital maintains an Outperform rating with $13.00 price target, while Leerink Partners lowered its target to $12.00. Moody's upgraded the corporate family rating to Ba2 from Ba3, supporting credit improvement.

A successful breakout above $11.12 resistance would target the conservative measured move of $12.19, representing 6.2% upside from current levels. The pattern suggests sustained breakout requires volume above the 1.57x ratio currently observed, validating institutional buying interest. RSI at 67.46 indicates emerging overbought conditions but remains below 70, leaving room for momentum continuation. Invalidation occurs if price closes below key support at $10.01, which would negate the ascending triangle structure. Historical data shows ascending triangles carry 63% win probability (matching this setup's score), with typical follow-through extending 4-8 weeks post-breakout.

The -$0.76 EPS result represented a 311% miss versus consensus, with RBC Capital attributing the decline to weaker-than-expected fourth-quarter print and steeper ramp to 2026 guidance. Fourth quarter EBITDA was impacted by $14.5 million legal settlement and over $10 million in strategic investments to onboard a new capitated contract—execution risk on this contract integration remains elevated. RSI at 67.46 approaches overbought, with Bollinger Band position at 1.177 indicating stretched valuation relative to bands. The sector regime is bearish (-0.33 regime score), and market regime is also bearish (-0.43), creating headwinds. Beta of 0.62 understates volatility; trailing beta shows 1.76 per recent filings, suggesting significant downside acceleration risk in adverse conditions. The healthcare services sector faces ongoing regulatory and reimbursement pressures. No earnings announcement is imminent, reducing near-term catalysts beyond the new capitated contract execution.